Shares of drugmaker Sanofi (SNY -1.15%) failed to keep up with the broader market in 2013, and the stock is down nearly 8% year to date. Disappointing guidance and the recent FDA rejection of multiple sclerosis treatment Lemtrada have driven shares down. However, is the market being myopic? Could Sanofi be positioned for growth, and are its shares valued attractively compared to its Big Pharma peers? Analysts Max Macaluso and David Williamson discuss this dividend stock in the following video.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Dividend Stock To Watch Today: Sanofi
This is why investors should get Sanofi on their watchlist.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.